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Abstract
We previously showed that adeno-associated virus 2 (AAV2) mediated subretinal delivery of human interferon-alpha (IFN-a)
could effectively inhibit experimental autoimmune uveoretinitis (EAU). In this study we investigated whether subretinal
injection of both AVV2.IFN-a and AAV2.IL-4 had a stronger inhibition on EAU activity. B10RIII mice were subretinally injected
with AAV2.IFN-a alone (1.5610
7 vg), AAV2.IL-4 alone (3.55610
7 vg), and AAV2.IFN-a combined with AAV2.IL-4. PBS, AAV2
vector encoding green fluorescent protein (AAV2.GFP) (5610
7 vg) was subretinally injected as a control. IFN-a and IL-4 were
effectively expressed in the eyes from three weeks to three months following subretinal injection of AAV2 vectors either
alone or following combined administration and significantly attenuated EAU activity clinically and histopathologically.
AAV2.IL-4 showed a better therapeutic effect as compared to AAV2.IFN-a. The combination of AAV2.IL-4 and AAV2.IFN-a was
not significantly different as compared to AAV2.IL-4 alone. There was no difference concerning DTH (delayed-type
hypersensitivity) reaction, lymphocyte proliferation and IL-17 production among the investigated treatment groups,
suggesting that local retinal gene delivery did not affect the systemic immune response.
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Introduction
Uveitis is a common eye disease [1] and is one of the major
causes of visual handicap within the working population world-
wide [2], often with an autoimmune cause [3]. Clinical features
include inflammation of the choroid and retina with cellular
infiltration and macular edema [4]. Treatment of uveitis
commonly involves the use of corticosteroids and other immuno-
suppressive agents [5]. However, long-term application of these
drugs frequently leads to adverse side effects systemically and
locally. Furthermore, not all uveitis patients appear to respond to
immunosuppressive treatment.
IFN-a has been shown to have immunoregulatory and
immunosuppressive effects, and has been shown to be beneficial
in the treatment of patients with uveitis [6,7]. In addition, Th1
cells have been shown to be responsible for the development of
uveitis and endogenous Th2 cells have been assigned a protective
role. In this regard, IL-4, a Th2-secreted anti-inflammatory
cytokine, may help to prevent the development of Th1 related
autoimmune diseases. Earlier studies have shown that IL-4 was
effective in the treatment of NOD mice, a spontaneous model of
autoimmune type 1 diabetes [8]. It was also effective in the
treatment of experimental autoimmune encephalomyelitis (EAE),
a well known model for multiple sclerosis [9].
Currently, gene therapy has achieved remarkable success in
human and animal models in various retinal diseases [10,11,12,13]
and some studies are now in the clinical trial stage [14].
Experimental autoimmune uveoretinitis (EAU), an animal
model that shares many features with human uveitic disorders
such as Behcet’s disease [15], can be induced in susceptible
animals such as the B10.RIII mouse strain by immunization with
retinal specific antigens that are often recognized immunologically
by lymphocytes of human uveitis patients including interphotor-
eceptor retinoid binding protein (IRBP) or its immunodominant
epitopes. Because of the clinical and pathological features in
common with human uveitis, EAU induced by IRBP in B10.RIII
mice is considered as a useful tool to explore new therapeutic
strategies. In the past several years, a few studies on AAV-
mediated gene therapy have been attempted in the EAU model
[16,17]. In a recent study we developed a recombinant AAV2
vector containing the human IFN-a gene and revealed that
subretinal injection of AAV2 vector harboring the IFN-a gene
showed a significant therapeutic effect on the development of EAU
[18].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37995In the current study, we examined if subretinal administration
of IFN-a combined with another immunoregulatory cytokine, IL-
4, would be more effective in the treatment of EAU in B10RIII
mice and if AAV-mediated transgene subretinal delivery had an




This study was carried out according to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research. The
study was specifically approved by the Ethics Committee of the
First Affiliated Hospital of Chongqing Medical University,
Chongqing, China (Permit Number: 2009-201009). All surgery
was performed under anesthesia, and all efforts were made to
minimize animal suffering.
Animals and Reagents
B10RIII mice were purchased from Jackson Laboratory (Bar
Harbor, ME). All animals were housed under standard (specific
pathogen free) conditions. Human interphotoreceptor retinoid
binding protein peptide spanning amino acid residues 161–180
(IRBP161–180, SGIPYIISYLHPGNTILHVD) was synthesized by
Shanghai Sangon Biological Engineering Technology & Services
Ltd. Co. Complete Freund’s adjuvant (CFA) containing 1.0 mg/
ml mycobacterium tuberculosis (H37RA, ATCC 25177) was
obtained from Sigma-Aldrich (St. Louis, MO).
Vectors
The recombinant adeno-associated virus vector harboring the
human interferon alpha 2a gene (AAV2.IFN-a) or mouse in-
terleukin-4 gene (AAV2.IL-4) was prepared according to pre-
viously mentioned methods [18] as follows. Total mRNAs were
extracted from human PBMCs and mouse splenocytes respectively
and first-strand cDNA was synthesized with the Superscript III
Reverse Transcriptase system (Invitrogen, Carlsbad, CA, USA).
The coding sequence of human interferon alpha 2a was obtained
from GenBank database (http://www.ncbi.nlm.nih.gov/genbank/
, GenBank accession number BC074936) and the specific primers
were designed (forward, 59 GGGGTACCATGGCCTT-
GACCTTTGCTTT 39 and reverse, 59 CTGTCGACT-
CATTCCTTACTTCTTAAACTTT 39) to amplify the human
IFN-a coding sequence. The mouse interleukin-4 coding sequence
was obtained from GenBank database (http://www.ncbi.nlm.nih.
gov/genbank/, GenBank accession number NM_021283) and was
PCR-amplified with the specific primers (forward, 59
GGGGGTACCATGGGTCTCAACCCCCAGC 39 and reverse,
59 TCTGTCGACCTACGAGTAATCCATTTGCATG 39). The
PCR product was inserted into pMD 18-T Vector (TaKaRa,
Japan). After DNA sequencing verification, the IFN-a or IL-4
coding sequence was obtained by digestion with KpnI and SalI, and
subcloned into an AAV2 expression plasmid backbone between
the sites of KpnI and SalI. Recombinant AAV vector containing the
IFN-a or IL-4 gene was prepared by using the triple transfection
procedure of 293 cells, followed by CsCl density gradients (Vector
Gene Technology Company Ltd (Beijing, China)).
Subretinal Injection
0.5 ml of AAV vector was injected subretinally into the right eye
of each B10RIII mouse, leaving the other eye as an internal
control. Subretinal injection was performed as previously de-
scribed [18,19] and all procedures were operated under sterile
conditions.
Assay of Interferon-a and Interleukin-4 in Injected Mice
Mice were sacrificed at various time points after subretinal
injection of AAV vectors. The undiluted serum was collected for
immunoassay. For ocular fluid samples, AAV vector injected eyes
and contralateral eyes were enucleated and ocular fluid samples
were prepared as previously described [18]. All procedures were
conducted on ice. IFN-a and IL-4 concentrations were de-
termined using commercially available ELISA kits according to
the manufacturer’s directions (PBL Interferon Source, USA). The
detection limits were 12.5 pg/ml and 15 pg/ml for IFN-a and
IL-4, respectively.
Induction and Clinical Assessment of EAU
Mice were immunized subcutaneously at the base of the tail and
both thighs with 50 mg human IRBP161–180 peptide in 100 ml PBS,
emulsified 1:1 v/v in complete Freund’s adjuvant (CFA) supple-
mented with 1.0 mg/ml Mycobacterium tuberculosis strain (MTB). A
total of 200 ml emulsion was given for one mouse. EAU activity
was examined clinically by slit lamp microscopy from day 8 to 21
after immunization. The clinical severity of ocular inflammation
was assessed by two independent observers in a masked manner,
and scored on a scale of 0–5 in half-point increments, according to
five separate criteria described previously [18].
Histopathology
Eyes were enucleated on day 14 following IRBP immunization
and were fixed in 4% buffered formaldehyde for 1 hour at room
temperature. Tissues were embedded in paraffin. Serial 4–6 mm
sections were cut through the papillary-optic nerve axis and
stained by haematoxylin and eosin. At least four sections of each
eye cut at different levels were prepared and evaluated histolog-
ically. The intensity of EAU was graded in a masked fashion on
a scale of 0 to 4, as described earlier [20]: (0) no change; (0.5) mild
inflammatory cell infiltration, no damage; (1) infiltration, retinal
folds and focal retinal detachments, few small granulomas in
choroid and retina, perivascularitis; (2) moderate infiltration,
retinal folds and detachments, focal photoreceptor cell damage,
small- to medium-sized granulomas, perivasculatis and vasculatis;
(3) medium to heavy infiltration, extensive retinal folding with
detachment, moderate photoreceptor cell damage, medium-sized
granulomatous lesions, subretinal neovascularization; (4) heavy
infiltration, diffuse retinal detachment with serous exudates and
subretinal bleeding, extensive photoreceptor cell damage, large
granulomatous lesion and subretinal neovascularization.
Delayed-type Hypersensitity (DTH)
Delayed-type hypersensitity (DTH) was assessed on day 19 after
immunization with IRBP161–180 peptide. 10 mg of IRBP161–180
Figure 1. Scheme of the AAV2 vector construct. The transgene is
under the control of a CMV promoter and followed by BGH poly (A). The
expression cassette is flanked by ITRs. CMV promoter, human
cytomegalovirus immediate early promoter; hIFN-a, human interferon-
alpha; BGH poly (A), BGH poly-adenylation signal; ITR, AAV2 inverted
terminal repeats.
doi:10.1371/journal.pone.0037995.g001
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mouse, the left pinna was injected with PBS as a control. Ear
thickness was measured 48 hours after IRBP161–180 peptide
challenge. The specific response was calculated as the difference
between ear thickness before and after the IRBP161–180 peptide
injection.
IRBP-specific Lymphocyte Responses
The spleen and draining lymph nodes were removed from
immunized mice on day 21. A single cell suspension was prepared
by mechanical disruption and followed by a passage through
a sterile stainless steel screen. For proliferation and cytokine assay,
cells (2610
6 cells/ml) were cultured in triplicate with RPMI 1640
medium (Gibco, Grand Island, NY, USA) containing 2 mM L-
glutamine, 5610
25 M 2-ME, 0.1 mM nonessential amino acids,
1 mM sodium pyruvate and 10% FBS in the presence of 10 mg/
ml IRBP161–180,1mg/ml Concanavalin A (Sigma) or medium
alone for 72 hours. Proliferation was detected by a modified MTT
Figure 2. The expression of transgenes following subretinal
injection. In the AAV2.IFN-a injected eyes, the level of IFN-a increases
from 14 days (the first time point tested) to three months after
injection. For the eyes receiving AAV2.IFN-a combined with AAV2.IL-4
injection, IFN-a level reaches a peak on day 42 and remains at
a moderate level until three months after injection (a). IL-4 expression is
similar in eyes receiving an injection of AAV2.IL-4 alone as compared to
eyes receiving AAV2.IL-4 combined with AAV2.IFN-a (b). Results are
expressed as the mean6standard deviation.
doi:10.1371/journal.pone.0037995.g002
Figure 3. Clinical evaluation of EAU activity. EAU was induced in
groups of mice receiving subretinal vector or PBS injection. Severe
uveitis is observed in the PBS (a) and AAV2.GFP injected eyes (b)a s
compared to the AAV vectors treated eyes (c–e). Three AAV vector
Gene Therapy in EAU
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described previously [21]. IL-17 concentration in the supernatants
was measured using a commercially available ELISA kit according
to the manufacturer’s directions (R&D System, Minneapolis, MN)
with a detection limit of 15 pg/ml.
Statistical Analysis
Severity of EAU was performed by the Kruskal-Wallis analysis
followed by the Mann-Whitney U test with Bonferroni correction.
DTH and IRBP-specific immune responses were analyzed using
ANOVA. P,0.05 was considered to be significantly different.
Data are expressed as mean6standard deviation (SD). All
experiments were repeated at least twice.
Results
AAV Vectors
The IFN-a or IL-4 gene was driven by the human cytomeg-
alovirus (CMV) promoter and was followed by a BGH poly(A)
signal (Fig. 1). Titers of recombinant vectors used were
3610
10 vg/ml and 7.1610
10 vg/ml for AAV2.IFN-a and AA-
V2.IL-4, respectively. AAV2.GFP was used as a vector control
(1610
11 vg/ml).
IFN-a and IL-4 Expression in vivo Following Subretinal
Injection of AAV Vectors
Mice were subretinally injected with AAV2.IFN-a (1.5610
7 vg)
alone, AAV2.IL-4 (3.55610
7 vg) alone, and AAV2.IFN-a com-
bined with AAV2.IL-4. Two weeks following subretinal injection,
the IFN-a and IL-4 level in ocular fluid samples obtained from
injected eyes was assayed by ELISA. Data showed that the
expression of IFN-a and IL-4 was detectable two weeks following
subretinal injection in each group. In the eye receiving an injection
of AAV2.IFN-a (1.5610
7 vg) alone, the level of IFN-a was
0.128 ng/ml on day 14, and 0.66 ng/ml on day 21 (Fig. 2a). The
level increased further up to day 42 and started declining on day
90. Following the combined AAV2.IFN-a and AAV2.IL-4 vector
injection, expression of IFN-a was observed on day 14, reached
a peak on day 42 and remained detectable until three months after
injection (Fig. 2a). For the expression of IL-4, the eyes injected
with the AAV2.IL-4 vector alone and injected with the combined
AAV2.IL-4 and AAV2.IFN-a showed a similar expression profile
from 14 days to three months after subretinal injection (Fig. 2b).
For all mice receiving subretinal injection of either AAV2.IFN-
a alone, AAV2.IL-4 (3.55610
7 vg) alone, or AAV2.IFN-a com-
bined with AAV2.IL-4, IFN-a or IL-4 remained undetectable in
undiluted serum and in the contralateral uninjected eyes over time
(data not shown).
The Effect of AAV Vectors on EAU
EAU was successfully induced in B10RIII mice following
immunization with 50 mg human IRBP161–180 peptide emulsified
in CFA as evidenced by conjunctival hyperemia, ciliary injection,
corneal edema, posterior synechiae, aqueous flare and cells. The
treated groups show significantly attenuated EAU over time as
compared with controls (f). Data are presented as mean6standard
deviation. The clinical score shows that compared with controls, the
AAV2.IFN-a treated group (p=0.019, Mann-Whitney U test), the
AAV2.IL-4 treated group (p,0.0001) and the combined treated group
(p,0.0001) developed a significantly reduced EAU (g). Each point
represents an individual eye. The average scores of each group are
denoted by the horizontal bars.
doi:10.1371/journal.pone.0037995.g003
Figure 4. Histological examinations on day 14 of EAU. Images of
histological analysis show severe intraocular inflammation in PBS (a,b)
and AAV2.GFP injected eyes (c,d) compared with AAV2.IFN-a treated
Gene Therapy in EAU
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following immunization, reached a peak by day 12 and was
followed by a gradual regression. None of the control mice
receiving CFA alone developed EAU.
To test the effect of AAV vectors on the development of EAU,
mice were divided into five groups. Three experimental groups
were subretinally injected with either AAV2.IFN-a alone, AA-
V2.IL-4 alone or AAV2.IFN-a combined with AAV2.IL-4.
Another group of mice was injected with AAV2.GFP as a vector
control and the fifth group consisted of control mice receiving
a subretinal injection with PBS. All groups of mice were
immunized with IRBP161–180 peptide emulsified in CFA three
weeks after subretinal vector or PBS injection.
Clinical signs were monitored after immunization by slit lamp
microscopy. In PBS or AAV2.GFP injected eyes, a severe
inflammatory reaction including conjunctival hyperemia, ciliary
injection, corneal edema, aqueous cells and posterior synechiae
was observed (Figs. 3a, b). A mild uveitis as manifested by
conjunctival hyperemia or ciliary injection was observed in
AAV2.IFN-a alone treated, AAV2.IL-4 alone treated, AA-
V2.IFN-a and AAV2.IL-4 combined treated eyes (Figs. 3c–e).
Severity of EAU was clinically scored on a scale from 0 to 5. A
significantly decreased activity of EAU throughout the course of
the disease was observed in the three AAV vector treated groups as
compared with the PBS or AAV2.GFP injected controls (Fig. 3f).
Clinical scoring on day 12 following EAU induction showed that
the severity of EAU in AAV2.IL-4 alone injected eyes and
AAV2.IL-4 combined with AAV2.IFN-a treated eyes was
significantly decreased when compared with PBS and AAV2.GFP
injected controls (p,0.0001). Eyes receiving an injection of
AAV2.IFN-a alone also showed a significantly decreased in-
flammation compared with the PBS (p=0.001) or AAV2.GFP
group (p=0.013). AAV2.IL-4 treatment showed a much more
dramatically increased blockade of EAU than AAV2.IFN-a treat-
ment (p=0.001). Subretinal injection of both AAV2.IL-4 and
AAV2.IFN-a showed a stronger inhibitory effect on EAU activity
as compared with AAV2.IFN-a administration alone (p,0.0001)
and a trend of increased inhibition when compared with
AAV2.IL-4 alone, although the difference did not reach statistical
significance. (Fig. 3g).
Histological analysis showed a severe uveitis in the AAV2.GFP
injected and PBS injected control mice as evidenced by massive
infiltration of inflammatory cells into the iris, vitreous cavity,
throughout all retinal layers and the choroid, intensive retinal
vasculitis, destruction of the retinal architecture with severe folding
and detachment, as well as photoreceptor damage (Figs. 4a–d).
However, in AAV2.IFN-a alone treated, AAV2.IL-4 alone
treated, AAV2.IFN-a and AAV2.IL-4 combined treated eyes,
only scattered infiltration of inflammatory cells into the vitreous
body and retina was observed (Figs. 4e, g, i). Additionally, the
inflammatory changes in the anterior segment of treated eyes were
less than those in the AAV2.GFP injected eye and PBS injected
eyes (Figs. 4f, h, j). Pathological grading showed that the
AAV2.IFN-a alone treated eyes showed a significantly decreased
uveitis when compared with PBS and AAV2.GFP injected controls
(p=0.01, p=0.012). AAV2.IL-4 alone injected eyes and AA-
V2.IL-4 combined with AAV2.IFN-a treated eyes showed more
significantly decreased inflammation compared with controls
(p,0.0001) than AAV2.IFN-a alone (Fig. 4k).
Effects of Subretinal Injection of AAV Vectors on the
IRBP-specific Systemic Immune Response
DTH reactions in vivo and lymphocyte responses to IRBP161–180
in vitro were assayed to evaluate the impact of AAV2 vector
subretinal injection on the systemic immune response. Results
showed that there was no significant difference in the DTH
reactions against IRBP between AAV2.IL-4 injected mice,
AAV2.IFN-a injected mice, AAV2.IL-4 combined with AA-
V2.IFN-a treated mice, AAV2.GFP injected control mice and
PBS injected controls (p.0.05) (Fig. 5 a).
Lymphocytes from spleen and lymph nodes were isolated and
incubated for 72 hours in vitro with IRBP161–180 peptide, ConA
(positive control), or medium alone (negative control) respectively.
The proliferation and IL-17 production of lymphocytes were
assayed in lymphocytes obtained from AAV2.IL-4 injected mice,
AAV2.IFN-a injected mice, AAV2.IL-4 combined with AA-
V2.IFN-a treated mice, AAV2.GFP injected control mice and
PBS injected controls. The result showed a similar response in
proliferation and IL-17 production of lymphocytes incubated with
ConA among the five groups of mice. A somewhat lower response
in IL-17 production and proliferation of lymphocytes was
observed in all the tested groups when exposed to IRBP161–180
peptide. There was no difference concerning IRBP-specific
lymphocyte proliferation and IL-17 production among all tested
groups (p.0.05) (Fig. 5 b,c). Lymphocytes from the tested groups
did not show a detectable proliferation and IL-17 production
when cultured with medium alone.
Discussion
In this study, we investigated the effect of ocular gene therapy
on the development of uveitis by subretinal injection of
recombinant AAV2 vector harboring genes encoding the immu-
noregulatory cytokines IFN-a and IL-4. Experiments were
designed to deliver AAV2.IFN-a alone, AAV2.IL-4 alone, and
AAV2.IFN-a combined with AAV2.IL-4, respectively. The results
showed an effective expression of the transgene for at least three
months without detectable spreading to the systemic circulation or
contralateral control eye. Subretinal administration of AAV2.IFN-
a alone, AAV2.IL-4 alone, and AAV2.IFN-a combined with
AAV2.IL-4 significantly reduced EAU development clinically and
histologically. The IFN-a and IL-4 combination vector showed
a somewhat more potent therapeutic effect on the development of
EAU as compared with the IL-4 vector alone, but the difference
did not reach statistical significance. It is possible that experiments
using lower amounts of vector would be able to show a synergistic
effect. Further studies are needed to address this issue.
Autoreactive effector CD4
+ T cells play a crucial role in the
pathogenesis of autoimmune and autoinflammatory uveitis.
Currently these effector cells are divided into the IFN-c producing
Th1, the IL-4 and IL-10 producing Th2, and the IL-17 producing
Th17 cells. Abundant evidence is now available to show that both
the Th1 and Th17 cells are responsible for uveitis whereas the Th2
cells are regulatory [22,23,24]. Most attention for the regulatory
capacity of Th2 cells has been directed towards a role for IL-10
[24] and the therapeutic use of IL-4 as mentioned in our study has
received little attention so far. Although some studies have
reported that the administration of recombinant cytokines showed
therapeutic efficacy in clinical uveitis [25], many therapeutic
(e,f), AAV2.IL-4 treated (g,h), and AAV2.IFN-a combined with AAV2.IL-4
treated eyes (i,j). (haematoxylin eosin staining, original magnifica-
tion6100). EAU was significantly reduced in AAV2.IL-4 treated group,
AAV2.IL-4 combined with AAV2.IFN-a treated group as compared with
controls (k)( p ,0.0001, Mann-Whitney U test). The AAV2.IFN-a treated
group also shows a significantly decreased uveitis (p=0.005). Each
point is the score of an individual eye. The mean scores of each group
are denoted by the horizontal bars.
doi:10.1371/journal.pone.0037995.g004
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the cytokine molecules and swift clearance from circulation.
Furthermore, extremely high doses are administered systemically
to reach a therapeutically active intraocular concentration of the
cytokine, and achieving such high systemic levels can potentially
result in deleterious side effects [26]. Our previous study showed
Figure 5. Systemic IRBP-specific immune responses in each group. DTH responses were elicited on day 19 of EAU and evaluated on day 21.
Data show no significant difference of ear swelling among all the tested groups (p.0.05) (a). IRBP-specific lymphocyte proliferation (b) and IL-17
production in vitro (c) show no significant difference among the five tested groups (P.0.05). Results are presented as mean6standard deviation. 5–6
animals per group were used and each experiment was performed three times.
doi:10.1371/journal.pone.0037995.g005
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retinal cells after subretinal injection of AAV2 vector containing
the IFN-a gene was able to suppress inflammation in mice
undergoing EAU [18]. Inflammation could however not to be
completely blocked by subretinal injection of AAV2.IFN-a and
a combination of immunoregulatory factors might be attempted to
get a better protection because of the complex interplay of both
pro- and anti-inflammatory molecules involved in EAU de-
velopment. We therefore designed experiments to explore whether
administration of IFN-a, combined with another immunoregula-
tory cytokine such as IL-4, could achieve a better therapeutic effect
on the development of EAU.
IFN-a in the treatment of uveitis has been widely reported in
the past several decades. According to previous reports, systemic
administration of IFN-a in patients with Behcet’s disease and other
immune-related disorders could help to upregulate Tregs and
inhibit IL-17-expressing cells [27,28,29]. Additionally, other
reports have shown that circulating levels of TNF-a and TNF-
a2R in patients with Behcet’s disease were decreased after IFN-
a treatment [30]. Another cytokine, IL-4, has been successfully
used in autoimmune animal models in the past few years [8,9,31].
Delivery of IL-4, basically, helps to excite a Th2 response and may
be beneficial in those autoimmune diseases, whose development
depends on the polarization of Th1 cells. Recently, IL-4 has been
reported to be able to induce the development of CD25+CD4 T
cells with regulatory capacity and that these cells play a prominent
role in the development of Ag-specific CD25+CD4 Tregs in vivo
[32], which has been thought protective to EAU. Local delivery of
IL-4 has been shown to increase the recruitment of Treg cells by
increasing the synthesis of chemo-attractant cytokines in inflamed
CNS areas [9]. Generally, contribution to upregulate the local
Treg population by IL-4 in vivo could be another arm of the anti-
inflammatory pathways. However, the expression of inflammatory
cytokines, chemokines as well as the target cell in ocular lesions
remains to be clarified and the exact mechanisms through which
IFN-a and IL-4 function in the treatment of EAU need to be
investigated further in future studies. Our current experiments
suggest that the inhibitory effect on the development of uveitis is
mediated via a local and not due to a systemic effect, since we were
not able to detect an effect of local cytokine vector delivery on the
DTH reaction against IRBP nor on the IRBP specific lymphocyte
response in mice undergoing IRBP induced EAU. Consistent with
these results, a similar phenomenon in this study and previous ones
is that AAV2-mediated transgene expression was restricted to the
injected eye without detectable spreading in the blood. The fact
that the systemic immune response is not affected by retinal gene
delivery may avoid the possibility of systemic immunosuppressive
side effects.
In conclusion, we have now confirmed that AAV2-mediated
subretinal delivery of IFN-a and IL-4 could effectively attenuate
EAU in mice in the absence of systemic immunosuppression. A
combined delivery of IL-4 and IFN-a did not result in a synergistic
effect. A further understanding of the exact mechanisms by which
the released IFN-a and IL-4 exactly inhibit EAU will contribute to
the development of efficient and safe retinal gene therapy in
uveitis.
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